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Background: Vascular access failure, a major cause of morbidity in hemodialysis
(HD) patients, occurs mainly at stenotic endothelium following an acute thrombo-
tic event. Microparticles (MPs) are fragments derived from injured cell membrane
and are closely associated with coagulation and vascular inﬂammatory responses.
Methods: We investigated the relationship between levels of circulating MPs and
vascular access patency in HD patients. A total of 82 HD patients and 28 healthy
patients were enrolled. We used ﬂow cytometry to measure endothelial MPs (EMPs)
identiﬁed by CD31þCD42 or CD51þ and platelet-derived MPs (PMPs) identiﬁed by
CD31þCD42þ in plasma samples of participants. Vascular access patency was deﬁned
as an interval from the time of access formation to the time of ﬁrst access stenosis in
each patient. MP counts were compared according to access patent duration.
Results: The levels of EMP (both CD31þCD42 and CD51þ) and CD31þCD42þPMP
were signiﬁcantly higher in patients than in healthy participants. Levels of
CD31þCD42EMP and CD31þCD42þPMP showed a positive correlation. In non-
diabetic HD patients, CD31þCD42EMPs and CD31þCD42þPMPs were more
elevated in the shorter access survival group (access survival o1 year) than in the
longer survival group (access survival Z 4 years).
Conclusion: Elevated circulating EMP or PMP counts are inﬂuenced by end-stage renal
disease and increased levels of EMP and PMP may be associated with vascular access
failure in HD patients.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Vascular access failure is the single-most important cause
of morbidity and hospitalization in patients receiving hemo-
dialysis (HD) [1]. Vascular stenosis and subsequentrean Society of Nephrology. P
ses/by-nc-nd/4.0/).
gy, Ewha Womans Uni-
angcheon-gu, Seoul, 158-
).thrombosis precede access failure, and venous neointimal
hyperplasia (VNH) is a main pathology of vascular stenosis in
both native arteriovenous ﬁstulas (AVF) and polytetraﬂuor-
oethylene grafts [2–4]. In VNH, injured endothelial cells
accelerate the expression of adhesion molecules and tissue
factors and increase activated platelet aggregation, ﬁnally
leading to regional stenosis and thrombosis [1]. Dialysis
patients tend to show thrombotic tendencies such as
enhanced platelet aggregation and hypercoagulability [5,6].
However, despite many efforts to clarify the relationshipublished by Elsevier. This is an open access article under the CC BY-NC-
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hemodialysis and thrombotic tendencies, there are insufﬁ-
cient data about what determines vulnerability to vascular
access failure in HD patients.
Elevated circulating microparticles (MPs) are associated
with many thrombotic diseases [7]. MPs are fragments
ranging in the size of 0.2–1.0 mm shed from the plasma
membrane in response to various stimuli such as activation or
apoptosis [8–10]. MPs have no nucleus, contain a membrane
skeleton, and express surface antigens speciﬁc for their
parental cells of platelets, endothelial cells, leukocytes, lym-
phocytes, and erythrocytes [11–13]. MPs were ﬁrst described
in 1967 by Wolf, and were called ‘‘platelet dusts’’ from
activated platelets [14]. However, MPs are not just byproducts
of activated or apoptotic cellular processes, but are actively
involved in the pathogenesis of many procoagulant diseases,
especially vascular diseases [7]. Platelet-derived MPs (PMPs)
were increased in myocardial infarction [15], hypertension
(HTN) [16], and diabetes mellitus (DM) [17], and elevated
endothelial MPs (EMPs) were closely associated with
endothelial dysfunction [10,18,19] and occurred in acute
coronary syndrome (ACS) [15,20], DM [21], chronic renal
failure (CRF) [22], and ESRD [10]. Thus, elevated EMPs or
PMPs could play an important role in cardiovascular diseases.
However, there are insufﬁcient studies about roles of elevated
MPs in ESRD patients, particularly the association between
MPs and vascular access failure.
In this study, we hypothesized that elevated levels of
EMP or PMP derived from activated injured endothelial
cells or platelets in patients receiving HD could be asso-
ciated with vascular access failure. We measured MP
counts (EMP and PMP) in HD patients and compared them
according to the duration of vascular access patency.Methods
Study population and study design
For our retrospective cross-sectional study, 82 clinically
stable patients receiving maintenance HD for more than
3 months in 00 Hospital were enrolled. The duration of HD
per session was 4–6 h and its frequency was individually
tailored to achieve a Kt/V41.2. The patients were treated
with synthetic membranes (polysulfone or polyamide) and
without dialyzer reuse. Heparinization during dialysis session
was done by continuous infusion using unfractionated
heparin at a dose of 500–1000 U/h, according to patient
weight. All patients did not have acute diseases such as
recent myocardial infarction, unstable angina, acute pulmon-
ary embolism, acute neurologic disorder, malignancies, or
overt systemic infections during the last 6 months. Vascular
access patency was deﬁned as an interval from the time of
access formation to the time of ﬁrst vascular stenosis in each
patient. To analyze the relationship between levels of MP and
vascular access patency, we divided the patients into two
subgroups with a reference point of 1-year access survival. In
detail, patients with access patency of more than 1 year at
enrollment were placed into Group A, and the others were
included in Group B (access survivalo1 year). In Group A,vascular access patency of more than 4 years was deﬁned as
Group C. We reviewed medical records of each patient and
examined the medical histories of DM, HTN, and drug
histories of renin-angiotensin system (RAS) blockers such as
angiotensin converting enzyme inhibitors (ACEi) or angioten-
sin receptor blockers (ARB), statins, and antiplatelet agents.
We assessed the nutritional status of each patient by measur-
ing normalized protein catabolic rate (nPCR). A total of 28
healthy people without a medical history of DM or HTN were
enrolled as controls. The study was performed according to
the principles of the Declaration of Helsinki after our Institu-
tional Review Board approval. Written informed consent was
obtained from all participants.
Blood sampling
Venous blood samples were taken from each patient before
starting the dialysis session and they were immediately
analyzed. Samples were obtained from the HD-needle punc-
ture site 72 h after the last dialysis. All patients were required
to have midnight fasting for 6 h or more. Standard laboratory
tests included complete blood cell and platelet counts and
blood chemistry including serum albumin, protein, blood urea
nitrogen (BUN), creatinine, cholesterol, and low-density lipo-
protein (LDL). High sensitive C-reactive protein (hsCRP) was
measured by a nephelometric immunoassay (Handok Pharm,
Seoul, Korea). Interleukin-6 (IL-6) levels were checked using a
commercial ELISA kit (Pierce Biotechnology, Rockford, IL, USA).
Preparation of microparticles (EMPs and PMPs)
Blood samples (5 mL) were drawn into citrated (blue-
top) Vacutainer tubes centrifuged for 10 min at 160g at 4 1C
to prepare platelet-rich plasma (PRP). The PRP was then
centrifuged for 6 min at 1200g at 4 1C to prepare platelet-
poor plasma (PPP). Supernatant was collected and assays of
EMPs and PMPs were performed within 1–2 h after obtain-
ing samples [20]. We detected EMPs using two different
markers, i.e., CD31 and CD51. PMPs were identiﬁed by the
marker CD42 [23]. CD31 is expressed on both EMPs and
PMPs, whereas CD42 is not expressed on endothelial cells,
so double labeling was required. CD51 expression is extre-
mely weak on platelets and is not detected with ﬂow
cytometry on PMPs; therefore, double-labeling was not
required [20]. In brief, EMPs were deﬁned as particles with
CD31þCD42 or CD51þ and PMPs were deﬁned as
particles with CD31þCD42þ [24] (Fig. 1).
Materials
Fluorescein isothiocyanate (FITC)-conjugated human
monoclonal antibody against avb3 [anti-CD51-FITC (clone
23C6, IgG1k)], phycoerythrin (PE)-conjugated human
monoclonal antibody against PECAM-1 [anti-CD31-PE
(clone WM59, IgG1k)], and FITC-conjugate human mono-
clonal antibody against leukocyte common antigen [anti-
CD45-FITC (clone HI30, IgG1k)] were purchased from BD
Bioscience (San Jose, CA, USA). FITC-conjugated human
monoclonal antibody against GPIba [anti-CD42b-FITC
(clone SZ2, IgG1)] from Beckman & Coulter (Marseillue,
Figure 1. Representative graph of ﬂow cytometry analysis
of microparticles. (A) The points in the right lower quadrant are
CD31þCD42EMPs. (B) The points in the right lower quadrant are
CD51þEMPs. (C) The right upper quadrant region contains
CD31þCD42þPMPs. EMPs, endothelial microparticles; PMPs, plate-
let-derived microparticles.
Kidney Res Clin Pract 31 (2012) 38–4740France), FITC- and PE-conjugated, isotype-matched mono-
clonal antibodies (clone MOPI-21, IgG1k) of irrelevant
speciﬁcity were purchased from BD Bioscience. Annexin
V (An-V)-FITC apoptosis detection kit was purchased from
Calbiochem (Darmstadt, Germany).Flow cytometry analysis of MPs
We performed an analysis of MPs using ﬂow cytometry
with FACScalibur (BD Biosciences). Each 40 mL of prepared
PPP in a 12 mm75 mm polypropylene tube was incu-
bated with either 4 mL of anti-CD42-FITC plus 4 mL of anti-
CD31-PE or 4 mL of anti-CD51-FITC for 20 min with gentle
regular shaking at room temperature. Then, 500 mL of
phosphate buffered saline (PBS) was added, and MPs of
each sample were analyzed by ﬂow cytometry at the
medium ﬂow setting. Light scatter and ﬂuorescence chan-
nels were set at logarithmic gain. Particles r1 mm deﬁned
by 1-mm calibrator beads (Polysciences, Warrington, PA,
USA) were identiﬁed in forward scatter and side scatter
intensity dot representation and gated as MPs. The ﬂuor-
escence-positive particles were further separated on
another histogram based on the size of this range. Sample
analysis was stopped after 10,000 events. Data were
analyzed using CELLQuest software (version 5.2, BD
Bioscience). FITC- and PE-conjugated isotype-matched
mouse monoclonal IgG was used for negative controls in
each sample. Because CD31 is also expressed on leuko-
cytes, ﬂow cytometric analysis with anti-CD45-FITC was
performed for exclusion of MPs from leukocytes.
Statistical analysis
Data are expressed as means 7SEM. The Student t test
or the w2 test was used for comparison between the two
groups. The Mann–Whitney U test was used for compar-
ison between the two groups for the nonparametric
analysis. The multiple linear regression analysis was
performed to evaluate correlated factors for increased
microparticle counts. The logistic regression analysis was
used to evaluate risk factors affecting vascular access
failure. Pearson’s correlation method was used for an
analysis of association between MP counts and continuous
variables. A P value of o0.05 was considered to be
statistically signiﬁcant. Statistical analysis was performed
with SPSS, version 13.0 (Chicago, IL, USA).Results
Comparison of levels of EMP and PMP between HD patients
and healthy participants
The baseline characteristics of enrolled participants are
shown in Table 1. The mean age of patients was higher
than controls and sex distribution was different. Mean
levels of serum albumin, cholesterol, LDL cholesterol,
hemoglobin, and platelets were higher in healthy partici-
pants compared with HD patients.
Both CD31þCD42EMP and CD51þEMP levels were
signiﬁcantly higher in HD patients than controls
(CD31þCD42EMPs: 176.4711.0 vs. 44.873.1 events/
10,000 events; Po0.001, CD51þEMPs: 34.972.0 vs.
25.472.1 events/10,000 events; P¼0.006). These results
are shown in Fig. 2A and B. Levels of CD31þCD42
EMP showed higher values than that of CD51þEMP.
CD31þCD42þPMP levels were also higher in HD patients
Table 1. Baseline Characteristics of HD Patients and Controlsa
Variables HD patients
(n¼82)
Healthy
controls
(n¼28)
P
Sex (men, %) 30 (36.6) 18 (64.3) 0.008
Age (years) 61.271.5 45.171.4 o0.001
Hypertension (%) 67 (81.7) 0
Diabetes (%) 41 (50.0) 0
Causes of ESRD (%) 0
Diabetes mellitus 42 (51.2)
Hypertension 26 (31.7)
Glomerulonephritis 5 (6.1)
Other causes 9 (11.0)
HD duration (years) 4.0 (1.1–21.6) 0
Usage of RAS blocker (%) 34 (41.5) 0
Usage of statin (%) 10 (12.2) 0
Usage of antiplatelet (%) 38 (46.3)
HD access type (%) 0
AVF 79 (96.3)
Kt/V 1.46 (1.05–2.20) ND
nPCR (g/kg/day) 1.06 (0.56–1.91) ND
BUN (mg/dL) 69.572.1 13.370.6 o0.001
Creatinine (mg/dL) 10.0270.34 0.9670.04 o0.001
Albumin (g/dL) 3.5970.07 4.5170.04 o0.001
Total cholesterol (mg/dL) 175.674.5 197.076.1 0.002
LDL cholesterol (mg/dL) 111.073.9 121.675.0 o0.001
Hemoglobin (g/dL) 10.4371.02 14.7771.68 o0.001
Platelet (103/mL) 188.679.8 221.979.0 0.003
a Data are presented as means7SEM or number (%).
AVF, arteriovenous ﬁstula; AVG, arteriovenous graft; BUN, blood urea
nitrogen; ESRD, end-stage renal disease; HD, hemodialysis; LDL, low
density lipoprotein; ND, not determined; nPCR, normalized protein
catabolic rate; RAS, renin–angiotensin system; SEM, standard error
of mean.
Figure 2. Comparison of EMP and PMP counts between patients on
hemodialysis and healthy controls. CD31þCD42EMPs (a); CD51þ
EMPs (b); and CD31þCD42þPMPs (c) levels were signiﬁcantly higher in
patients on hemodialysis compared with controls. Data are expressed as
means 7SEM. nPo0.01 vs. control. EMPs, endothelial microparticles;
PMPs, platelet-derived microparticles; SEM, standard error of mean.
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10,000 events; Po0.001). These results are shown in
Fig. 2C. In measured MPs, CD45þMPs (common leukocyte
marker) were rare (0–0.05%), suggesting that detected
CD31þCD42-MP originated from endothelial cells.
An age-matched subgroup analysis was also performed
after excluding participants above 50 years old (n¼20 in
HD patients group; n¼23 in control group), which pro-
vided similar mean ages for both groups (44.271.0 years
in patients vs. 42.370.7 years in controls; P¼0.118).
Levels of CD31þCD42EMP and CD31þCD42þPMP
were signiﬁcantly higher in HD patients than controls
(CD31þCD42EMPs: 194.1716.7 vs. 45.873.3 events/
10,000 events; Po0.001, CD31þCD42þPMPs: 277.47
37.5 vs. 195.679.5 events/10,000 events; Po0.001),
but levels of CD51þEMP were not signiﬁcantly different
between the two groups (30.072.3 vs. 25.772.4
events/10,000 events; P¼0.196). These results are shown
in Fig. 3.
Because both DM and HTN can elevate circulating EMP or
PMP counts [16,17,25,26] a subgroup analysis was performed
after excluding patients with DM or HTN. The levels of
CD31þCD42EMP, CD51þEMP, and CD31þCD42þPMP in
non-DM HD patients were also higher than controls
(CD31þCD42EMPs: 194.0713.9 vs. 44.073.1 events/
10,000 events; P¼0.006, CD51þEMPs: 34.372.7 vs.
25.472.1 events/10,000 events; P¼0.014, CD31þCD42
þPMPs: 257.5722.1 vs. 187.1710.7 events/10,000 events;
P¼0.006). These results are shown in Fig. 4A. When HTNpatients were excluded, the levels of CD31þCD42EMP and
CD31þCD42þPMP were higher in patients than controls
(CD31þCD42EMPs: 238.6726.4 vs. 44.073.1 events/
10,000 events; Po0.001, CD31þCD42þPMPs: 274.3731.9
vs. 187.1710.7 events/10,000 events; P¼0.019). These
results are shown in Fig. 4B. CD51þEMPs were also slightly
higher in patients (32.472.8 vs. 25.472.1 events/10,000
events; P¼0.057). Excluding DM and HTN patients,
CD31þCD42EMP and CD31þCD42þPMP counts were still
higher in HD patients (CD31þCD42EMPs: 255.173.9 vs.
44.073.1 events/10,000 events; Po0.001, CD31þCD42
þPMPs: 281.1750.1 vs. 187.1710.7 events/10,000 events,
P¼0.007). These results are shown in Fig. 4C. In an age-
matched subgroup reanalysis that excluded DM patients, only
Figure 3. Comparison of EMP and PMP levels between patients on
hemodialysis and healthy participants o 50 years old. CD31þ
CD42EMPs (a) and CD31þCD42þPMPs (b) levels were signiﬁcantly
higher in patients on hemodialysis compared with controls. Data are
expressed as means 7SEM. nPo0.01 vs. control. EMPs, endothelial
microparticles; PMPs, platelet-derived microparticles; SEM, standard
error of mean.
Figure 4. Comparison of EMP and PMP levels between patients on
hemodialysis and healthy participants after excluding patients with
diabetes mellitus or hypertension. (A) MPs of 3 markers in patients
without diabetes mellitus (n¼41) were signiﬁcantly higher than
healthy participants (n¼28). (B) The levels of CD31þCD42EMP and
CD31þCD42þPMP were signiﬁcantly higher in normotensive patients
on hemodialysis (n¼15) compared with the controls (n¼28). (C) When
patients with diabetes mellitus and hypertension were excluded, levels
of CD31þCD42EMP and CD31þCD42þPMP were signiﬁcantly
higher in patients on hemodialsis (patients, n¼8; controls, n¼28).
Data are expressed as means 7SEM. nPo0.01 vs. control. nnPo0.05 vs.
control. EMP, endothelial microparticles; MP, microparticle; PMP,
platelet-derived microparticles; SEM, standard error of mean.
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DM HD patients group than in healthy participants
(201.2726.9 vs. 45.873.3 events/10,000 events, Po0.001).
In multivariate analysis regarding age, sex, DM, HTN, ESRD,
use of antiplatelet agent, ESRD was signiﬁcantly associated
with both CD31þCD41EMP and CD31þCD41þPMP, but
not CD51þEMP counts (Table 2).
Correlation between MP counts and values in HD patients
In HD patients, there were no signiﬁcant correlations
between MP (both EMP and PMP) counts and blood
pressure, serum glucose, albumin, cholesterol, LDL, hemo-
globin, platelet, hsCRP, and IL-6 levels (data not shown).
Neither EMP counts nor PMP counts were different
between the DM and non-DM patients groups. Interest-
ingly, CD31þCD42EMP and CD31þD42þPMP levels
showed a positive correlation (b¼0.672, Po0.001). These
results are shown in Fig. 5.
Association between MP levels and vascular access patency in
HD patients
A total of 77 patients were included for analysis of the
relationship between MP levels and vascular access
patency. The clinical characteristics and laboratory data
of these participants are shown in Table 2. Neither EMP
nor PMP levels showed signiﬁcant differences betweenGroup A (vascular access patency longer than 1 year) and
Group B (vascular access patency shorter than 1 year). The
percentage of patients with DM was higher in Group B, but
Kt/V, BUN, creatinine, total cholesterol, LDL cholesterol,
hemoglobin, platelets, hsCRP, and IL-6 levels were similar.
Next, we compared patients with Group B (shorter
access survival group, access survivalo1 year with one
vascular access creation) with Group C (longer access
survival group, access survivalZ4 years with one vascular
access creation). Clinical characteristics and laboratory
Table 2. Multivariate Analysis of Risk Factors for Increased
microparticles
Risk factors b 95% CI P
(A) Risk factors for increased CD31þCD42EMP
Age 0.055 –0.90–1.71 0.539
Male sex 0.006 –31.30–33.83 0.937
ESRD 0.766 122.69–241.12 o0.001
DM –0.111 –60.55–13.23 0.206
HTN 0.298 16.33–110.11 0.009
Use of antiplatelet agent 0.179 0.82–77.05 0.054
(B) Risk factors for increased CD51þEMP
Age 0.094 –0.16–0.37 0.422
Male sex –0.172 –12.12–1.05 0.098
ESRD 0.157 –6.14–17.31 0.347
DM 0.032 –6.92–9.02 0.794
HTN 0.053 –7.89–11.33 0.723
Use of antiplatelet agent 0.172 –2.39–14.09 0.164
(C) Risk factors for increased CD31þCD42þPMP
Age 0.052 –1.46–2.37 0.640
Male sex 0.080 –28.02–67.50 0.414
ESRD 0.225 2.13–129.50 0.041
DM 0.007 –52.34–55.97 0.947
HTN –0.024 –74.93–62.75 0.861
Use of antiplatelet agent 0.230 3.21–115.13 0.038
CI, conﬁdence interval; EMP, endothelial microparticle; ESRD, end-
stage renal disease; DM, diabetes mellitus; HTN, hypertension; PMP,
platelet-derived microparticle.
Figure 5. Correlations between markers of microparticles. (A)
CD31þCD42EMP and CD31þCD42þPMP showed positive correla-
tion. (B) CD31þCD42EMP and CD51þEMP showed no signiﬁcant
correlation. EMP, endothelial microparticle; PMP, platelet-derived
microparticle.
Table 3. Comparison of Variables Between Shorter Vascular Access
Survival Group (o 1 year) and the longer survival group (Z
4 years)a
Variables Vascular access patency P
Group B Group C
(o1 year,
n¼18)
(4 4 years,
n¼18)
Male sex (%) 8 (44.4) 3 (16.7) 0.070
Age (years) 65.373.1 54.973.0 0.022
Hypertension (%) 14 (77.8) 14 (77.8) 1.000
Diabetes (%) 13 (72.2) 7 (38.9) 0.044
HD duration (years) 4.5470.76 7.9171.02 0.012
Access patent interval (M) 4.770.8 95.977.0 o0.001
Usage of RAS blocker (%) 7 (38.9) 8 (44.4) 0.735
Usage of statin (%) 0 (0) 2 (11.1) 0.486
Usage of antiplatelet (%) 11 (61.1) 6 (33.3) 0.095
AVF (%) 17 (94.4) 18 (100) 1.000
Kt/V 1.4970.07 1.6270.06 0.191
nPCR (g/kg/day) 1.1870.08 1.1470.06 0.624
BUN (mg/dL) 69.775.2 72.172.9 0.689
Creatinine (mg/dL) 9.870.6 10.470.6 0.462
Albumin (g/dL) 3.6270.10 3.8670.06 0.043
Total cholesterol (mg/dL) 172.779.7 162.1716.4 0.582
LDL cholesterol (mg/dL) 98.6715.7 100.2711.2 0.934
Hemoglobin (g/dL) 10.670.3 10.570.2 0.873
Platelet (103/mL) 191.579.7 174.4713.7 0.314
EMP CD31þCD42- 206.1723.1 154.6714.6 0.068
CD51þ 37.572.9 31.873.5 0.226
PMP CD31þCD42þ 296.6733.7 229.7732.1 0.159
hsCRP (mg/dL) 0.3270.07 0.1570.06 0.091
IL-6 ELISA (pg/mL) 13.2474.85 2.8171.01 0.044
a Data are presented as means7SEM or number (%).
AVF, arteriovenous ﬁstula; BUN, blood urea nitrogen; ELISA, enzyme-
linked immunosorbent assay; EMP, endothelial microparticle; HD,
hemodialysis; hsCRP, high sensitive C-reactive protein; IL-6, interleu-
kin-6; LDL, low-density lipoprotein; nPCR, normalized protein cata-
bolic rate; PMP, platelet-derived microparticle; RAS, renin–angiotensin
system; SEM, standard error of mean.
Table 4. Comparison of MPs and IL-6 Levels Between Shorter
Vascular Access Survival group (o1 year) and Longer Survival
Group (Z4 years) in HD Patients without Diabetes Mellitusa
Variables Vascular access patency P
Group B without
DM
Group C without
DM
(o1 year,
n¼5)
(4 4 years,
n¼11)
EMP CD31þCD42 265.4733.8 151.9719.4 0.007
CD51þ 39.072.4 29.574.7 0.188
PMP CD31þCD42þ 393.6754.9 187.5734.5 0.005
IL-6 ELISA (pg/mL) 5.1871.36 1.5270.40 0.036
hsCRP (mg/dL) 0.2070.09 0.0770.02 0.115
a Data are presented as means7SEM.
DM, diabetes mellitus; ELISA, enzyme-linked immunosorbent assay;
EMP, endothelial microparticle; hsCRP, high sensitive C-reactive pro-
tein; IL-6, interleukin-6; PMP, platelet-derived microparticle; SEM,
standard error of mean.
J-H Ryu et al / Association between vascular access failure and microparticles 43data of the participants are summarized in Table 3.
CD31þCD42EMP counts were slightly higher in Group
B than group C (P¼0.068). Age and the percentage of
patients with DM were higher in Group B. IL-6 levels were
signiﬁcantly higher in Group B, and HD duration was
longer in Group C. Excluding DM patients, the levels of
Table 5. Logistic Analysis of Risk Factors for 2-year Vascular Access Failure in the HD Patients Group
Risk factors Simple model Multiple model
OR 95% CI P OR 95% CI P
Logistic analysis with EMP
DM 1.79 0.69–4.65 0.233 1.92 0.65–5.69 0.238
HTN 1.18 0.36–3.88 0.791 1.32 0.29–5.98 0.719
Old age (450 years) 5.31 1.13–24.98 0.035 6.86 1.21–38.84 0.029
CD31þCD42EMP
o25% 1.00 1.00
25–50% 0.94 0.23–3.90 0.929 1.14 0.23–5.59 0.877
50–75% 1.00 0.24–4.18 1.000 1.02 0.21–4.95 0.981
475% 2.73 0.72–10.27 0.138 5.81 1.11–23.48 0.037
CD51þEMP
o25% 1.00 1.00
25–50% 1.41 0.33–5.98 0.644 0.57 0.09–3.65 0.551
50–75% 2.50 0.60–10.34 0.206 1.25 0.25–6.33 0.785
475% 1.88 0.45–7.82 0.388 0.74 0.14–4.09 0.731
Logistic analysis with PMP*
DM 1.79 0.69–4.65 0.233 1.55 0.56–4.32 0.472
HTN 1.18 0.36–3.88 0.791 1.71 0.44–6.65 0.437
Old age (450 years) 5.31 1.13–24.98 0.035 6.10 1.19–31.39 0.030
CD31þCD42þPMP
o25% 1.00 1.00
25–50% 0.94 0.20–4.41 0.939 0.72 0.14–3.63 0.692
50–75% 2.67 0.65–10.97 0.174 2.06 0.47–9.12 0.341
475% 3.00 0.74–12.11 0.123 3.00 0.68–13.16 0.145
DM, diabetes mellitus; EMP, endothelial microparticle; HTN, hypertension; PMP, platelet-derived microparticle.
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IL-6 levels were signiﬁcantly elevated in Group B (Table 4).
MP as a risk factor for 2-year vascular access failure
We performed univariate and multivariate logistic
analysis about risk factors such as DM, HTN, old age
(450 years old), and levels of each MP (EMP or PMP)
for vascular access failure. This analysis was based on the
vascular access failure within 2 years from the ﬁrst access
creation because the median value of access patent inter-
val in HD patients group was 2 years. We divided the MP
levels of three markers into the quartile group. Among the
risk factors, old age and the fourth quartile (475%) group
of CD31þCD42EMP levels were signiﬁcant risk factors
for 2-year vascular access failure (Table 5).Discussion
The present study showed that HD patients had higher
levels of circulating EMP and PMP than healthy partici-
pants. When diabetic or hypertensive patients were
excluded, this association was also preserved. In an age-
matched subgroup analysis, CD31þCD42EMP and PMP
counts were also elevated in HD patients whereas
CD51þEMP counts were not. This study suggests the
possibility that ESRD induces EMP and PMP generation.
These ﬁndings correspond with the results from several
previous studies. Levels of circulating EMP (CD144þ and
CD146þ) in CRF or HD patients were more elevated than
in healthy controls [22]. In another study, levels of
circulating MP derived from platelets (CD31þCD41þ),
red blood cells, and endothelial cells (CD31þCD41 and
CD144þ) derived from patients with ESRD were higherthan healthy participants [10]. Elevated PMP counts also
related to uremia [27]. It is not clear why PMP or EMP
counts are higher in uremic patients. Reduced shear stress
on vessel walls in ESRD patients was suggested as a
determining factor for circulating EMP counts in vivo
[28]. Alternatively, high shear stress in atherosclerotic
arteries of most ESRD patients activated platelets, gener-
ating PMPs [29]. Moreover, PMP levels were not different
according to renal replacement therapy (HD or peritoneal
dialysis) or before and after HD [30]. Further work is
necessary to determine the factors that directly inﬂuence
MP generation in ESRD patients.
Increased levels of EMP were associated with vascular
diseases such as ACS [15,20] DM [21], lupus [31], and
preeclampsia [32]. Increased PMP counts were also asso-
ciated with thrombotic diseases such as venous throm-
boembolism [33], peripheral artery disease [34], coronary
artery disease [35], and cerebrovascular infarction [36].
High levels of EMP or PMP reﬂect impaired endothelial
dysfunction or abnormally increased thrombotic propen-
sity. Vascular diseases showed elevated circulating EMP
and PMP counts and cardiovascular diseases are known as
a leading cause of death in uremic patients [37]; thus,
increased EMPs or PMPs might be important markers of
thrombogenic propensities in HD patients.
We found elevated CD31þCD42EMP levels in HD
patients, but CD51þEMP counts were not in age-matched
subgroup analysis, even when excluding DM and HTN
patients. CD31þCD42EMP values were higher than
CD51þEMP in each sample; CD51þEMP counts were only
approximately 20% of CD31þCD42EMP counts, consis-
tent with a previous result of Bernal–Mizrachi’s study
[20]. Moreover, there was no signiﬁcant relationship
between CD31þCD42EMPs and CD51þEMPs. There
are two possible explanations for these ﬁndings. Firstly,
J-H Ryu et al / Association between vascular access failure and microparticles 45CD31þCD42 could be better marker of EMP than
CD51þ to discriminate the pathologic condition. Second,
different species of EMP exist, and there are discrepancies
in phenotypes of surface antigens expressed on MPs
derived from endothelial cells [20,38]. Different EMP
species can reﬂect different kinds of endothelial injury,
e.g., elevated CD31þEMP levels reﬂect acute endothelial
injury, whereas CD51þEMP levels are associated chronic
inﬂammation [20]. Because we did not measure acute
thrombosis, it is not certain whether CD31þCD42EMP
may also reﬂect acute vascular events in ESRD patients.
However, CD31þCD42EMP counts were increased in
the shorter vascular access survival group, suggesting that
it may be a better marker for reﬂecting vulnerability to
vascular access failure in HD patients.
However, there was a signiﬁcant correlation between
CD31þCD42EMP counts and CD31þCD42þPMP counts.
This ﬁnding can imply that both CD31þCD42EMP and
CD31þCD42þPMP are proportionally induced via coinciden-
tal endothelial and platelet injury in uremic condition. So,
uremia can induce EMP and PMP simultaneously. However,
more investigations are required to prove a deﬁnite correla-
tion between EMP and PMP because it has been reported that
EMPs can be induced by hemodialysis itself [28].
In this study, we aimed to determine the relationship
between levels of MP and vascular access survival. In non-
DM HD patients, CD31þCD42EMP and CD31þCD42þ
PMP were signiﬁcantly higher in the shorter access survi-
val group (o1 year) than the longer access survival group
(Z4 years). Despite the relatively small sample size of the
shorter survival group, to our knowledge this study is the
ﬁrst report to show the positive relationship between high
circulating MP (both EMP and PMP) levels and shorter
vascular access survival. There were several previous
studies to deﬁne the association between increased levels
of circulating MP in uremic patients and vascular diseases.
Increased EMP counts in ESRD patients are closely asso-
ciated with vascular dysfunction [10] and elevated
endothelial adhesion molecules [39,40]. Higher circulating
EMPs can inhibit endothelial NO pathway and surrogate
markers of endothelial dysfunction in cardiovascular dis-
eases in ESRD [10]. Elevated levels of PMP also relate to
thrombotic diseases. For example, elevated PMP counts
were higher in uremic patients with thrombotic events
[30], whereas another recent study reported that PMP
counts were not associated with shorter vascular access
survival in HD patients [41]. It was not clear whether PMP
counts relate to vascular access patency in HD patients.
However, we found a relationship between high PMP
counts and shorter vascular access survival, as well as a
positive correlation between CD31þCD42EMP and
CD31þCD42þPMP. The uremic environment of coexis-
tent uremic toxins, increased proinﬂammatory cytokines,
and systemic atherosclerosis increases EMP counts due to
endothelial injury and increased PMP counts from acti-
vated platelets may trigger thrombotic accidents in ure-
mic patients [30].
There are some limitations to this study. First, this
study was a retrospective cross-sectional study. Therefore,
the effect of increased MP levels as a risk factor forvascular access failure was not deﬁnitively investigated
in our study. Second, MP levels at the point of obtaining
blood samples from each patient may not represent
exactly the point of vascular access failure. Circulating
MPs are cleared by phagocytes to prevent tissue inﬂam-
mation [42], and this process may be quick. Measuring
MPs at the time that stenotic or occlusive problems of
vascular access developed may show a better correlation
to vascular access failure. Third, MP levels at the time of
access formation were not measured; thus, the baseline
degrees of MP release of patients could not be provided.
Finally, we did not measure objective indexes for vascular
function other than taking histories of vascular access
failure or physical examination.
Despite the fact that ﬂow cytometry is an easy and fast
methodology for MP measurement, there is no standar-
dized absolute value to deﬁne pathologic MPs. However,
measurement of EMP and PMP counts could allow non-
invasive study of endothelial injuries and act as a good
diagnostic tool for detection of thrombotic propensities in
cardiovascular diseases, including renal disease.
In conclusion, our study showed that ESRD increased
EMP and PMP counts in HD patients. Elevated levels of
circulating EMPs and PMPs were associated with early
vascular access failure in HD patients.Conﬂict of interest
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